宜搜科技(02550.HK)夥華爲雲供應商超算科技發行RWA
宜搜科技(02550.HK)公佈,7月23日,與超算科技(華爲雲解決方案供應商之一)註冊成立Novus Infusion,其主要業務將爲發行現實世界資產「RWA」,雙方分別持股60%及40%。
同日,Novus Infusion與Greenland LPF訂立贊助協議,據此,雙方同意合作開發及實施以區塊鏈技術爲基礎的RWA平臺,專注於非物質文化知識產權的代幣化及管理,以及相關數位資產項目。完成後,平臺的衍生知識產權將由雙方共同擁有,目前預期協議項目的預算總額將少於500萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.